Zofran
Multiple Sclerosis (MS) Secondary Progressive
Tr1X, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Multiple Sclerosis (MS) Secondary Progressive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Remibrutinib Moein Amin | Phase 3 | BB |
Bendamustine Tr1X, Inc. | Phase 1/2 | CC |
hbi0101 cart Polina Stepensky | Phase 1 | CC |
Dasatinib Ohio State University | Phase 1 | CC |
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Ohio State University | Phase 1 | CC |
s103 cells Xijing Hospital | Phase 1 | CC |
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →